Economic evaluations of pancreatic cancer screening: a systematic review protocol

TY - JOUR

T1 - Economic evaluations of pancreatic cancer screening: a systematic review protocol

AU - Wittram, Robert

AU - König, Hans-Helmut

AU - Brettschneider, Christian

N1 - © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2024/8/17

Y1 - 2024/8/17

N2 - INTRODUCTION: The early detection of pancreatic cancer is an important step in reducing mortality by offering patients curative treatment. Screening strategies in risk populations and by means of different detection methods have been economically evaluated. However, a synthesis of screening studies to inform resource allocation towards early detection within the disease area has not been done. Therefore, studies evaluating the cost-effectiveness and costs of screening for pancreatic cancer should be systematically reviewed.METHODS AND ANALYSIS: A systematic review of economic evaluations reporting the cost-effectiveness or costs of pancreatic cancer screening will be conducted. The electronic databases Medline, Web of Science and EconLit will be searched without geographical or time restrictions. Two independent reviewers will select eligible studies based on predefined criteria. The study quality will be assessed using the Consolidated Health Economic Evaluation Reporting Standards statement and the Bias in Economic Evaluation checklist. One reviewer will extract relevant data and a second reviewer will cross-check compliance with the extraction sheet. Key items will include characteristics of screened individuals, the screening strategies used, and costs, health effects and cost-effectiveness as study outputs. Differences of opinion between the reviewers will be solved by consulting a third reviewer.ETHICS AND DISSEMINATION: Ethics approval is not required for this study since no original data will be collected. The results will be disseminated through presentations at conferences and publication in a peer-reviewed journal. The results of the systematic review will inform future economic evaluations of pancreatic screening, which provide guidance for decision-making in healthcare resource prioritisation.PROSPERO REGISTRATION NUMBER: CRD42023475348.

AB - INTRODUCTION: The early detection of pancreatic cancer is an important step in reducing mortality by offering patients curative treatment. Screening strategies in risk populations and by means of different detection methods have been economically evaluated. However, a synthesis of screening studies to inform resource allocation towards early detection within the disease area has not been done. Therefore, studies evaluating the cost-effectiveness and costs of screening for pancreatic cancer should be systematically reviewed.METHODS AND ANALYSIS: A systematic review of economic evaluations reporting the cost-effectiveness or costs of pancreatic cancer screening will be conducted. The electronic databases Medline, Web of Science and EconLit will be searched without geographical or time restrictions. Two independent reviewers will select eligible studies based on predefined criteria. The study quality will be assessed using the Consolidated Health Economic Evaluation Reporting Standards statement and the Bias in Economic Evaluation checklist. One reviewer will extract relevant data and a second reviewer will cross-check compliance with the extraction sheet. Key items will include characteristics of screened individuals, the screening strategies used, and costs, health effects and cost-effectiveness as study outputs. Differences of opinion between the reviewers will be solved by consulting a third reviewer.ETHICS AND DISSEMINATION: Ethics approval is not required for this study since no original data will be collected. The results will be disseminated through presentations at conferences and publication in a peer-reviewed journal. The results of the systematic review will inform future economic evaluations of pancreatic screening, which provide guidance for decision-making in healthcare resource prioritisation.PROSPERO REGISTRATION NUMBER: CRD42023475348.

KW - Humans

KW - Pancreatic Neoplasms/diagnosis

KW - Systematic Reviews as Topic

KW - Cost-Benefit Analysis

KW - Early Detection of Cancer/economics

KW - Research Design

KW - Mass Screening/economics

U2 - 10.1136/bmjopen-2024-087003

DO - 10.1136/bmjopen-2024-087003

M3 - SCORING: Journal article

C2 - 39153777

VL - 14

SP - e087003

JO - BMJ OPEN

JF - BMJ OPEN

SN - 2044-6055

IS - 8

ER -